Hematological Malignancy
2
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Astellasisavuconazonium sulfate - intravenous
Fate TherapeuticsGenetically engineered NK cells
Clinical Trials (2)
Total enrollment: 49 patients across 2 trials
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Start: Oct 2017Est. completion: Jul 201949 patients
Phase 1Completed
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Start: Oct 2019Est. completion: Apr 2020
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space